AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day. The retirement question is simple: which one belongs in an income-focused portfolio right now?

AbbVie’s cross, formed around July 7, is clean and widening: the 50-day is 222.91 versus a 200-day of 222.66, with both lines rising. Baxter’s cross is a different picture. The 50-day at 19.85 is only fractionally above a 200-day at 19.26, and the 200-day is still declining. Remember that golden crosses are lagging momentum indicators. They say nothing about cash flow or dividend safety. So the verdict has to come from fundamentals.

Dimension 1: Dividend Durability and Yield

AbbVie just declared its $1.73 quarterly payout, with an ex-dividend date of July 15, 2026, and payment on August 14, 2026. That annualizes to $6.92, extending a 13-year streak of increases dating to the 2013 Abbott spinoff, with the most recent hike a 5.5% bump. At the current price of $244.78, that represents a yield near 2.8%.

Baxter is the opposite story. Management slashed the quarterly dividend to $0.01 alongside Q4 2025 results, effectively eliminating the payout. Annualized, that is $0.04 per share.

The winner is AbbVie, decisively. Retirees writing checks from portfolio income cannot use a token dividend.

Dimension 2: Financial Stability and Balance Sheet

AbbVie is a $432.5 billion mega-cap with TTM revenue of $62.82 billion, an operating margin of 26.6%, and a beta of 0.283, roughly one-quarter of the market’s volatility. Yes, book value is negative from buyback and Allergan-era leverage, but cash generation covers the dividend comfortably.

Baxter carries a market cap of just $11.3 billion, TTM EPS of −$1.91, and a profit margin of −9.7%. FY 2025 GAAP net income was −$900 million after $485 million in goodwill impairments and $290 million in intangible impairments. Q1 2026 revenue increased 2.9% year over year, while adjusted EPS dropped roughly 35%.

Clearly, AbbVie wins again.

Dimension 3: Growth Outlook and Risks

AbbVie’s immunology franchise is doing the heavy lifting. Skyrizi grew 30.9% to $4.48 billion, and Rinvoq rose 23.3% to $2.12 billion in Q1 2026, more than offsetting Humira’s 38.6% biosimilar erosion. With the Q1 report, management raised full-year adjusted EPS guidance to $14.08 to $14.28. The consensus price target of $265.50 compares with the most recent close at $244.78.

Baxter’s 2026 guidance calls for reported sales flat to up 1% and adjusted EPS of $1.85 to $2.05, a step-down from $2.27. Overhangs include the Novum IQ LVP pump shipment hold, tariff pressure, and the reset following the January 2025 Kidney Care sale to Carlyle. New CEO Andrew Hider only took over in September 2025. The $21.71 analyst consensus target is a bit less than the current price.

Here again, AbbVie is the winner.

The Verdict

AbbVie wins across all three dimensions that matter for a retirement portfolio: a growing, well-covered dividend, mega-cap balance sheet stability with a low 0.28 beta, and a double-digit growth engine that has already prompted a guidance raise. The stock has returned 27.8% over the past year and 478.9% over 10 years, including reinvested momentum.

Baxter is a speculative turnaround play. The shares are down 73.1% over five years and 53.4% over a decade. A razor-thin golden cross against a declining 200-day line does not change the underlying picture: negative earnings, an eliminated dividend, and a new CEO writing a new operating model.

For a deep-value investor with a multi-year horizon and no need for income, Baxter may be defensible. For anyone drawing retirement income, AbbVie is the answer.

Contact [email protected] for any questions or corrections.